Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.58 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29598250 | 0.90 | MAPK1 (0.61) | NPC1RXFP1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL21033709 | 0.86 | TDP1 (0.59) | NPC1RXFP1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL24975198 | 0.84 | TP53 (0.56) | NPC1RXFP1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL29854270 | 0.84 | MAPK1 (0.54) | NPC1RXFP1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL4412321 | 0.84 | MAPT (0.55) | NPC1RXFP1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL24975195 | 0.84 | MAPK1 (0.54) | NPC1RXFP1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL6714830 | 0.84 | RXFP1 (0.75) | NPC1RXFP1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL2715851 | 0.84 | LDHA (0.67) | NPC1RXFP1RAB9AMAPK1KDM4E | |
| SCHEMBL2010059 | 0.84 | NPC1 (0.61) | NPC1RXFP1PTPN1PTPN6PTPN11 | |
| SCHEMBL2267893 | 0.84 | LMNA (0.53) | NPC1RXFP1PTPN1PTPN6PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112048734-B | Regioselective electrochemical synthesis method of nitrogen-containing aromatic heterocyclic carboxylic ester | 四川大学 | 2022-06-10 | — | — | CN | disclosed |
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-1436249-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2003027061-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | NPC1 2540/4885RXFP1 4354/4885PTPN1 2196/4885 |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HCAR1, H1-0, HDAC1 | NPC1 2441/4885RXFP1 412/4885PTPN1 3205/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | NPC1 2435/4885RXFP1 4582/4885PTPN1 2547/4885 |
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | NPC1 812/4885RXFP1 779/4885PTPN1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.